Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 19, 2025 that it ranked #304 on the 2025 Deloitte Technology Fast 500™. The ranking is based on percentage revenue growth from fiscal year 2021 to 2024, during which Catalyst reported 249% revenue growth. The company attributes the growth to portfolio momentum and commercial execution and noted this is the second consecutive year it earned a Fast 500 placement, improving from #452 in 2024. The announcement frames the recognition as evidence of sustained commercial progress and operational discipline while reaffirming commitment to patients and long-term growth.
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha annunciato il 19 novembre 2025 che si è classificata al #304 nella Deloitte Technology Fast 500™ 2025. La classifica si basa sulla crescita percentuale dei ricavi dal periodo fiscale 2021 al 2024, durante il quale Catalyst ha riportato una crescita dei ricavi del 249%. L'azienda attribuisce la crescita al momento del portafoglio e all'esecuzione commerciale, e osserva che questo è il secondo anno consecutivo in cui ottiene una posizione nel Fast 500, migliorando da #452 nel 2024. L'annuncio presenta il riconoscimento come prova di un progresso commerciale sostenuto e di una disciplina operativa, riaffermando al contempo l'impegno verso i pazienti e la crescita a lungo termine.
Catalyst Pharmaceuticals (Nasdaq: CPRX) anunció el 19 de noviembre de 2025 que se ubicó en el #304 de Deloitte Technology Fast 500™ 2025. El ranking se basa en el crecimiento porcentual de ingresos desde el año fiscal 2021 a 2024, periodo en el que Catalyst reportó un crecimiento de ingresos del 249%. La compañía atribuye el crecimiento a la inercia de su cartera y a la ejecución comercial y señaló que este es el segundo año consecutivo que obtiene una plaza en Fast 500, mejorando desde el #452 en 2024. El anuncio enmarca el reconocimiento como evidencia de un progreso comercial sostenido y de disciplina operativa, al tiempo que reafirma el compromiso con los pacientes y el crecimiento a largo plazo.
Catalyst Pharmaceuticals (나스닥: CPRX)가 2025년 11월 19일에 2025 Deloitte Technology Fast 500™에서 #304를 기록했다고 발표했습니다. 이 순위는 회계연도 2021년에서 2024년까지의 매출 성장률을 기준으로 하며, 그 기간 동안 Catalyst의 매출은 249%의 성장세를 보고했습니다. 회사는 포트폴리오의 모멘텀과 상업적 실행 덕분이라고 설명하고, 이는 Fast 500에 연속으로 선정된 두 번째 해이며 2024년의 #452에서 상승했다고 덧붙였습니다. 이 발표는 지속적인 상업적 진전과 운영 규율의 증거로서의 인정을 제시하면서 환자에 대한 약속과 장기 성장에 대한 의지를 재확인합니다.
Catalyst Pharmaceuticals (Nasdaq : CPRX) a annoncé le 19 novembre 2025 qu'elle s'est classée au #304 du Deloitte Technology Fast 500™ 2025. Le classement est basé sur la croissance du chiffre d'affaires en pourcentage sur l'exercice 2021 à 2024, période au cours de laquelle Catalyst a enregistré une croissance de ses revenus de 249%. L'entreprise attribue cette croissance à la dynamique de son portefeuille et à l'exécution commerciale, et note qu'il s'agit de la deuxième année consécutive où elle figure dans le Fast 500, en progression par rapport au #452 en 2024. L'annonce présente cette reconnaissance comme une preuve de progrès commercial soutenu et de discipline opérationnelle, tout en réaffirmant son engagement envers les patients et la croissance à long terme.
Catalyst Pharmaceuticals (Nasdaq: CPRX) gab am 19. November 2025 bekannt, dass sie sich auf dem #304 im Deloitte Technology Fast 500™ 2025 platziert hat. Die Rangliste basiert auf dem prozentualen Umsatzwachstum von dem Geschäftsjahr 2021 bis 2024, in dem Catalyst ein Umsatzwachstum von 249% meldete. Das Unternehmen führt das Wachstum auf die Dynamik des Portfolios und die kommerzielle Umsetzung zurück und stellte fest, dass dies das zweite aufeinanderfolgende Jahr ist, in dem es eine Fast 500-Platzierung erreicht, aufsteigend von #452 im Jahr 2024. Die Ankündigung rahmt die Anerkennung als Beweis für anhaltende kommerzielle Fortschritte und operative Disziplin, während sie gleichzeitig das Engagement für Patienten und langfristiges Wachstum bekräftigt.
Catalyst Pharmaceuticals (Nasdaq: CPRX) أعلنت في 19 نوفمبر 2025 أنها حلت في المرتبة #304 ضمن Deloitte Technology Fast 500™ لعام 2025. تعتمد المرتبة على معدل نمو الإيرادات بالنسبة للسنة المالية 2021 إلى 2024، حيث سجلت Catalyst نموًا في الإيرادات قدره 249%. تعزو الشركة النمو إلى زخم المحفظة والتنفيذ التجاري وتلاحظ أن هذه هي السنة الثانية على التوالي التي تحصل فيها على مكانة في Fast 500، محققة تحسنًا من #452 في 2024. يصوغ الإعلان الإطار كدليل على تقدم تجاري مستمر وانضباط تشغيلي، مع إعادة التأكيد على الالتزام تجاه المرضى والنمو على المدى الطويل.
- Revenue +249% FY2021–FY2024
- Ranked #304 on 2025 Deloitte Technology Fast 500
- Improved from #452 in 2024 to #304 in 2025
- None.
Attributes
CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the 2025 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. This achievement is based on percentage of revenue growth from fiscal year 2021 to 2024. Catalyst grew
Catalyst’s President and Chief Executive Officer, Rich Daly, credits Catalyst’s best-in-class product portfolio and outstanding commercial capabilities for the Company’s
“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”
Catalyst previously ranked 452 as a Deloitte Technology Fast 500 award winner for 2024.
About the 2025 Deloitte Technology Fast 500
Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2021 to 2024.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US
Please see www.deloitte.com/us/about for a detailed description of their legal structure.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull or Olipriya Das, Russo Partners (858) 717-2310, 646 942 5588 david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com
FAQ
What did Catalyst Pharmaceuticals (CPRX) announce on November 19, 2025?
How much did CPRX revenue grow between fiscal years 2021 and 2024?
How did Catalyst's Deloitte Fast 500 ranking change from 2024 to 2025?
Why does the Deloitte Technology Fast 500 ranking matter for CPRX investors?
When was Catalyst's Fast 500 recognition publicly announced?
What drivers did Catalyst cite for its 249% revenue growth?
